

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/774,176	
	Filing Date	February 6, 2004	
	First Named Inventor	Carroll, Miles W.	
	Art Unit	Not yet assigned	
	Examiner Name	Unknown	
Total Number of Pages in This Submission	10	Attorney Docket Number	021911-000510US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of Form PTO 1449, Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Kawai Lau	Reg. No. 44,461
Signature		
Date	May 11, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Timothy S. Parker		
Signature		Date	May 11, 2004



Whereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021911-000510US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450

On May 11, 2004

TOWNSEND and TOWNSEND and CREW LLP

By: *Timothy J. Parker*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Miles W. Carroll, et al.

Application No.: 10/774,176

Filed: February 6, 2004

For: POLYPEPTIDE

Examiner: Not yet assigned

Art Unit: Not yet assigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached copies of form PTO 1449 are being called to the attention of the Examiner. These references were cited in Information Disclosure Statements filed in conjunction with the parent application (Application No. 09/533,798, filed March 24, 2000, Attorney Docket No. 021911-000500US), dated August 11, 2000 and September 6, 2000, respectively, and were considered by the Examiner during the prosecution of the aforementioned parent application. In accordance with 37 CFR §1.98(d), copies of the references can be found in said parent application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required for submission of this statement because this submission is before the mailing of a first Office Action on the merits.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kawai Lau
Reg. No. 44,461

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 858-350-6100
Fax: 415-576-0300
KL:tp
60211407 v1

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

INFORMATION DISCLOSURE CITATION

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1643

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	5,118,672	06/92	Schinazi et al.	514	47	

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	A2	99/15684	04/99	WIPO				
	A3	99/15683	04/99	WIPO				
	A4	89/07947	09/89	WIPO				
	A5	92/03568	03/92	WIPO				


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


	A6	Guschlbauer et al., "Poly-2'-deoxy-2'-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic Characterization and interaction with poly-inosinic acid" 1977 Nucleic Acids Res. 4:1933						
	A7	Schibahara et al., "Site-directed cleavage of RNA" 1987 Nucleic Acids Res. 15:4403						
	A8	Gershon et al., "The nucleotide sequence around the capripoxvirus thymidine kinase gene reveals a gene Shared specifically with leporipoxvirus" J. Gen. Virol. 70:525, 1989						
	A9	Weir et al., "Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous Frameshift mutations" J. Virol. 46:530, 1983						
	A10	Esposito et al., "Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses" Virology 135:561, 1984						
	A11	Kilpatrick et al., "Cloning and physical mapping of yada monkey tumor virus DNA" Virology 143:399, 1985						
	A12	Binns et al., "Comparison of a conserved region in fowlpox virus and vaccinia virus gnomes and the translocation of the fowlpox virus thymidine kinase gene" J. Gen. Virol. 69:1275, 1988						
	A13	Schnitzlein et al., "A rapid method for identifying the thymidine kinase genes of avipoxviruses" J. Virological Method 20:341, 1988						
	A14	Fathi et al., "Efficient targeted insertion of an unselected marker into the vaccinia virus genome" Virology 97-105, 1986						

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO 0449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
 INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Miles William CARROLL et al.			
		FILING DATE 3/24/2000		GROUP ART UNIT 1643	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	A15	Graham et al., "A new technique for the assay of infectivity of human adenovirus 5 DNA" Virol. 52, 456-467, 1973			
	A16	Stralbinger et al., "Liposomes as carriers for intracellular delivery of nucleic acids" Methods in Enzymology, 101: 512-527 1983			
	A17	Studier et al., "Use of T7 RNA polymerase to direct expression of cloned genes" Methods in Enzymol. 185: 60-89, 1990			
	A18	Matthias et al., "Eukaryotic expression vectors for the analysis of mutant proteins" 1989 NAR 17, 6418			
	A19	Wootton & Federhen, "Statistics of local complexity in amino acid sequences and sequence database" 1993, Computers and Chemistry 17:149-163			
	A20	Myers et al., "Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein" 1994 J. Biol. Chem 169:9319-9324			
	A21	Starzynska et al., "Prognostic significance of 5T4 oncofetal antigen expression in colorectal" Br. J. Cancer 1994 May; 69(5):899-902			
	A22	Starzynska et al., "The expression of 5T4 antigen in colorectal and gastric carcinoma" Br. J. Cancer 1992 Nov; 66(5):867-869			
	A23	Hobbs et al., "polynucleotides containing 2'-amino-2'-deoxyribose and 2'-azido-2'-deoxyribose" 1973 Biochemistry 12:5138			
	A24	Starzynska et al., "5T4 oncofetal antigen in gastric carcinoma and its clinical significance" Eur J. Gastroenterol Hepatol 1998 Jun;10(6):479-484			
	A25	Carsberg et al., "Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells" 1996, Int J Cancer Sep 27; 68(1):84-92			
	A26	Yewdell et al., "TAP-independent delivery of antigenic peptides to the endoplasmic reticulum: therapeutic potential and insights into TAP-dependent antigen processing" 1998 J Immunotherapy 21:127-31			
	A27	Calvert et al., "Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens" J. of Virol 67:3069-3076, 1993			
	A28	Carroll et al., "Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen" 1998 J. Natl. Cancer Inst. 90(24):1881-1887			
	A29	"Two bright new faces in gene therapy" Nature Biotechnology 1996 14; 556			
EXAMINER			DATE CONSIDERED		
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					

Form PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 078883/0120	SERIAL NO. 09/533,798
			APPLICANT Miles William CARROLL et al.	
			FILING DATE 3/24/2000	GROUP ART UNIT 1643
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	A30	Pieken et al., "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes" 1991 Science 253:314-317		
	A31	Parker et al., "Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains" 1994 J. Immunol. 152:163-175		
	A32	Fu et al., "An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope" 1998 J. Virol 72:1469-81		
	A33	Schodel et al., "hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety" 1996 Intervirology 39:104-10		
	A34	Wolff and Trubetskoy, "The cambrian period of nonviral gene delivery" 1998 nature Biotechnology 16:421-423		
	A35	Taylor et al., "Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species" 1995 Vaccine 13:539-549		
	A36	Stannard et al., "Evidence for incomplete replication of a penguin poxvirus in cells of mammalian origin" J. Gen. Virol. 1998 79:1637-46		
	A37	Mackett et al., "Vaccinia virus: a selectable eukaryotic cloning and expression vector 1982 PNAS 79: 7415-7419		
	A38	Upton et al, "Identification and nucleotide sequence of the thymidine kinase gene of Shope fibroma virus" J. Virology 60:920, 1986		
	A39	Boyle et al, "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases" Virology 156:355-365, 1987		
	A40	Lewis et al, "Human immunodeficiency virus infection of cells arrested in the cell cycle" 1992 EMBO J 11:3053-3058		
	A41	Lewis and Emerman "Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus" 1994 J. Virol. 68:510-516		
	A42	Mackett et al, "General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes" 1984, J. Virol. 49:857-864		
EXAMINER			DATE CONSIDERED	
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.				

MAY 13 2004

Sheet 4 of 6

Form PTO-149
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

078883/0120

SERIAL NO.

09/533,798

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Miles William CARROLL et al.

FILING DATE

3/24/2000

GROUP ART UNIT

1643

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A43

Hruby et al, "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene"
PNAS 80:3411-3415, 1983

A44

Lytvyn et al, "Comparison of the thymidine dinase genes from three entomopoxiruses" J. Gen Virol
73:3235-3240 1992

A45

Smith et al., "Vaccinia virus immune evasion" 1997, Immunol Rev. 159:137-154

A46

Jenkins et al, "Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus"
AIDS Research and Human Retroviruses 7:991-998, 1991

A47

Taylor et al, "Recombinant fowlpox virus inducing protective immunity in non-avian species" Vaccine 6:497-
503, 1988

A48

Sphener et al. and Bournnell et al, "Insertion of the fusion gene from newcastle disease virus into a non-
essential region in the terminal repeats of fowlpox virus and demonstration of protective immunity induced by
The recombinant" 1990 J. Gen. Virol. 71:621-628

A49

Nakano et al, "Molecular genetics of vaccinia virus: demonstration of marker rescue" Proc. Natl. Acad. Sci.
USA 79, 1593-1596, 1982

A50

Chakrabarti et al., "Vaccinia virus expression vector: coexpression of β -galactosidase provides visual
screening of Recombinant virus plaques" Mol. Cell. Biol. 3403-3409, 1985

A51

Wigler et al, "Transformation of mammalian cells with genes from procaryotes and eucaryotes" Cell 777-785,
1979

A52

Graessmann et al, "Microinjection of tissue culture cells" Meth. Enzymology 101, 482-492, 1983

A53

Franke et al, "Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia
virus recombinants" Mol Cell biol 1918-1924, 1985

A54

Altenburger, W., Suter, C.P. and Altenburger J., "Partial deletion of the human host range gene in the
attenuated vaccinia virus MVA" 1989 Arch. Virol. 105, 15-27


EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/533,798	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Miles William CARROLL et al.			
				FILING DATE 3/24/2000		GROUP ART UNIT 1643	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A55	Neumann et al., "Gene transfer into mouse lyoma cell by electroporation in high electric fields" EMBO J. 1, 841-845, 1982					
	A56	Schaffner, "Direct transfer of cloned genes form bacteria to mammalian cells" Proc. Natl. Acad. Sci. USA 77,2163-2167, 1980					
	A57	Nestle FO et al, "Vaccinatio of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells" Nat. Med. 1998 Mar;4(3):328-32					
	A58	Altschul et al, "Issues in searching molecular sequence database" 1994 Nature Genetics 6;119-129.					
	A59	Carroll & Moss, "Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line", 1997 Virology 238:198-211					
	A60	Kim CJ et al., "Dendritic cell infected with poxviruses encoding Mart-1/melan a sensitive T Lymphocytes in vitro" J. Immunother, 1997 Jul;20(4):276-86					
	A61	Schneider et al., "enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara" 1998 Nat Med 4:397-402					
	A62	Chakrabarti et al, "Compact, synthetic, vaccinia virus early/late promoter for protein expression" 1997 Biotechniques 23:1094-1097					
	A63	Wyatt et al., "Development of replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model" 1996 Vaccine 14:1451-1458					
	A64	Sutter et al, "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain Of vaccinia virus stimulates protective immunity in mice to influenza virus", 1994 Vaccine 12:1032-1040					
	A65	Carroll and Moss "E. coli β -glucuronidase (GUS) as a marker for recombinant vaccinia viruses" 1995 Biotechniques 19:352-355					
	A66	Hirsch et al., "Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara" 1996 J. Virol 70:3741-3752					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/533,798	
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				APPLICANT Miles William CARROLL et al.			
				FILING DATE 3/24/2000		GROUP ART UNIT 1643	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A67	Sutter and Moss, "Nonreplicating vaccinia vector efficiently expresses recombinant genes" 1992 Proc. Natl. Acad Sci USA 89:10847-10851					
	A68	Bronte et al., "Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine" 1997, Proc. Natl Acad Sci USA 94(7):3183-3188					
	A69	Wyatt et al., "Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells" 1995 Virology 210:202-205					
	A70	Carroll et al., "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model" 1997 Vaccine, 15:387-394					
	A71	Sutter et al., "Non-replication vaccinia vector efficiently expresses bacteriophage T7 RNA polymerase" 1995 FEBS lett. 371:9-12					
	A72	Overwijk et al., "gp100/pmel 17 is a murine tumor rejection antigen induction of "Self" - reactive, tumoricidal T cells using high-affinity, altered peptide ligand", (1998) J. Exp. Med. 188: 277-286					
	A73	Hole N, and Stern PL, "Isolation and characterization of 5T4, a tumor-associated antigen", (1990) Int. J. Cancer 45(1): 179-184					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 078883/0120		SERIAL NO. 09/533,798	
 INFORMATION DISCLOSURE CITATION				APPLICANT Miles William CARROLL and Kevin Alan MYERS		GROUP ART UNIT 1643	
				FILING DATE March 24, 2000			
Date Submitted to PTO: September 6, 2000							
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	A1	EP-A-0198328	04/02/86	Europe			
	A2	EP-A-0110385	11/29/83	Europe			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							